We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Peptide from Umbilical Cord Blood Shuts Down a Neutrophil Inflammatory Factor

By LabMedica International staff writers
Posted on 19 Sep 2016
Image: Infection fighting cells from umbilical cord blood (left) and circulating blood three days after birth (right) from the same prematurely born baby. Umbilical cord blood has high levels of neonatal NET inhibitory factor (nNIF), which inhibits formation of neutrophil extracellular traps (NETs) (Photo courtesy of Mark Cody/Diana Lim, University of Utah Health Care).
Image: Infection fighting cells from umbilical cord blood (left) and circulating blood three days after birth (right) from the same prematurely born baby. Umbilical cord blood has high levels of neonatal NET inhibitory factor (nNIF), which inhibits formation of neutrophil extracellular traps (NETs) (Photo courtesy of Mark Cody/Diana Lim, University of Utah Health Care).
Researchers have isolated a peptide in umbilical cord blood that blocks the formation of neutrophil extracellular traps (NETs) and reduces inflammation and risk of developing sepsis.

NETs are molecular lattices of decondensed chromatin embedded with histones, granule enzymes, and antimicrobial peptides that are extruded by immune system neutrophil granulocytes, (polymorphonuclear leukocytes or PMNs) to capture and contain bacteria, viruses, and other pathogens. Experimental evidence has indicated that NETs also cause inflammatory vascular and tissue damage, suggesting that identifying pathways that inhibit NET formation may have therapeutic implications.

After examining various potential sites for the presence of a NET inhibitor, investigators at University of Utah Health Care (Salt Lake City, USA) discovered a peptide in umbilical cord blood that inhibited NET formation in vitro and in vivo and that appeared to be an endogenous regulator of NET generation.

They reported in the September 6, 2016, online edition of The Journal of Clinical Investigation that in addition to this neonatal NET-inhibitory factor (nNIF), they had also identified additional nNIF-related peptides (NRPs) that inhibited NET formation. These nNIFs and NRPs blocked NET formation induced by pathogens, microbial toxins, and pharmacologic agonists in vitro and in mouse models of infection and systemic inflammation, and they improved mortality in mouse models of systemic inflammation.

"We found something we were not expecting, and it has taken us to new strategies for therapy that did not exist before," said senior author Dr. Guy Zimmerman, professor of internal medicine at University of Utah Health Care.

Related Links:
University of Utah Health Care

New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Gold Member
Aspiration System
VACUSAFE
New
Urine Analyzer
respons® UDS100
New
Pipette Calibration System
Artel PCS®

Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more